[{"address1": "112-970 Burrard Street", "address2": "Unit 1290", "city": "Vancouver", "state": "BC", "zip": "V6Z 2R4", "country": "Canada", "phone": "778-731-1711", "website": "https://www.nervgen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael  Kelly", "age": 57, "title": "CEO, President & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 540130, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.66, "open": 1.65, "dayLow": 1.63, "dayHigh": 1.65, "regularMarketPreviousClose": 1.66, "regularMarketOpen": 1.65, "regularMarketDayLow": 1.63, "regularMarketDayHigh": 1.65, "beta": 1.432, "volume": 10650, "regularMarketVolume": 10650, "averageVolume": 80977, "averageVolume10days": 110450, "averageDailyVolume10Day": 110450, "bid": 1.63, "ask": 1.66, "askSize": 40000, "marketCap": 117034336, "fiftyTwoWeekLow": 1.16, "fiftyTwoWeekHigh": 2.99, "fiftyDayAverage": 1.5396, "twoHundredDayAverage": 1.672565, "currency": "USD", "enterpriseValue": 83852880, "floatShares": 55077114, "sharesOutstanding": 69927600, "heldPercentInsiders": 0.23042, "heldPercentInstitutions": 5e-05, "impliedSharesOutstanding": 71362400, "bookValue": 0.269, "priceToBook": 6.0966544, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -20018498, "trailingEps": -0.25, "enterpriseToEbitda": -4.66, "52WeekChange": 0.309237, "SandP52WeekChange": 0.2586832, "exchange": "OQB", "quoteType": "EQUITY", "symbol": "NGENF", "underlyingSymbol": "NGENF", "shortName": "NERVGEN PHARMA CORP", "longName": "NervGen Pharma Corp.", "firstTradeDateEpochUtc": 1554298200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c643fe7c-bc4e-3aef-b13f-5cf62f2bcc81", "messageBoardId": "finmb_577702483", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.64, "recommendationKey": "none", "totalCash": 30303990, "totalCashPerShare": 0.433, "ebitda": -17993496, "totalDebt": 174804, "quickRatio": 2.355, "currentRatio": 2.415, "debtToEquity": 0.929, "returnOnAssets": -0.44291002, "returnOnEquity": -1.3947501, "freeCashflow": -1385973, "operatingCashflow": -9761332, "financialCurrency": "CAD", "trailingPegRatio": null, "__fetch_time": "2024-06-21"}]